The Bispecific Approach, Interviews with Merus, Genmab and NovalGen
Interviewee/Contributor
Bill Lundberg, Tahamtan Ahmadi and Amit Nathwani
Organisation
MedNous
Cancer (Oncology)
Why we should take a second look at RNA therapeutics
Interviewee/Contributor
Gabriele Campi
Organisation
AurorA Science
Technology Transfer: Partnering with the US National Cancer Institute
Interviewee/Contributor
Michael Salgaller, Michele Newton and Michael Pollack
Organisation
US National Cancer Institute
Building biotech using an oncology network
Interviewee/Contributor
Jónas Einarsson
Organisation
Oslo Cancer Cluster, Radforsk
Drug development robust, despite the pandemic
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Developing radionuclide PARP inhibitors
Interviewee/Contributor
Greg Mullen
Organisation
Theragnostics Ltd
The linker matters in antibody-drug conjugates
Interviewee/Contributor
Philipp Spycher
Organisation
Araris Biotech AG
The hunt for the perfect tumour-associated antigen
Interviewee/Contributor
Erik Manting
Organisation
DCPrime BV
Oncology approvals are on an upward trend
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
A new paradigm for cancer therapy emerges
Interviewee/Contributor
Victoria English
Organisation
MedNous